← Back to Search

Unknown

ME3183 for Plaque Psoriasis

Phase 2
Waitlist Available
Research Sponsored by Meiji Pharma USA Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 20
Awards & highlights

Study Summary

This trial will test a new drug for plaque psoriasis in adults to see if it is safe and effective.

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 20
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 20 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI) Score (PASI-75) at Week 16 from Baseline
Secondary outcome measures
Change from Baseline in affected Body Surface Area (BSA) at all visits from Week 1 to Week 16
Change from Baseline in the Itch Numerical Rating Scale (NRS) at all visits from Week 1 to Week 16
Percent change from Baseline in PASI score at all visits from Week 1 to Week 16
+5 more

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: ME3183 Dose 4, QDExperimental Treatment1 Intervention
Specified dose of ME3183 capsule for 16 weeks
Group II: ME3183 Dose 3, BIDExperimental Treatment1 Intervention
Specified dose of ME3183 capsule for 16 weeks
Group III: ME3183 Dose 2, QDExperimental Treatment1 Intervention
Specified dose of ME3183 capsule for 16 weeks
Group IV: ME3183 Dose 1, BIDExperimental Treatment1 Intervention
Specified dose of ME3183 capsule for 16 weeks
Group V: PlaceboPlacebo Group1 Intervention
Placebo capsule of ME3183 for 16 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ME3183
2022
Completed Phase 2
~140

Who is running the clinical trial?

Meiji Pharma USA Inc.Lead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are seniors being invited to participate in this experiment?

"This clinical trial is only accessible to select individuals aged 18-75. There are 31 studies designed for persons under the legal age of consent and 142 trials suitable for those exceeding 65 years old."

Answered by AI

What is the enrollment number for this medical trial?

"Affirmative. According to clinicaltrials.gov, this research project is still enrolling participants and was initially posted on March 24th 2022. The last update for the trial occurred on September 1st 2022, with 125 patients needed from 28 different sites."

Answered by AI

Has the FDA sanctioned ME3183 for clinical use?

"As ME3183 is currently in its second phase of clinical trials, there is evidence to suggest it is safe but limited data indicating effectiveness. On a scale from 1 to 3, our team at Power estimates this medication's safety as 2."

Answered by AI

What criteria must potential participants satisfy to be eligible for this medical experiment?

"To be eligible to partake in this trial, an individual must have been diagnosed with psoriasis and lie within the age range of 18-75. This investigation will include a total of 125 people."

Answered by AI

Does this experiment currently have any openings for volunteers?

"According to clinicaltrials.gov, this research project is currently recruiting participants and was initially posted on March 24th 2022. The trial details have been recently updated on September 1st 2022."

Answered by AI

Are any Canadian healthcare centers conducting this investigation?

"At present, 28 sites are recruiting participants for this trial. These include Cobourg, Edmonton and Spokane as well as other centres. For convenience sake, it is recommended to select the nearest clinic so that travelling needs are kept to a minimum."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
Center for Clinical Studies LTD, LLP
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1

What questions have other patients asked about this trial?

How much time does it require?
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
2022. "Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05268016.
~43 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top